Non-lesional Atopic Dermatitis Skin Is Characterized by Broad Terminal Differentiation Defects and Variable Immune Abnormalities
Mayte Suárez‐Fariñas(Rockefeller University), Emma Guttman‐Yassky(Rockefeller University)
Cited by 457
Related Papers
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
|Journal of the American Academy of Dermatology|2018|334